Phase I study of neo-adjuvant chemoradiation therapy for newly diagnosed malignant astrocytomas

Phase I study of neo-adjuvant chemoradiation therapy for newly diagnosed malignant astrocytomas - neoadjuvant chemoradiation for malignant astrocytomas

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015566

Enrollment

Registered

2014-11-01

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant astyrocytomas

Interventions

day 1-30 Temozolomide 75mg/m2, once daily day 15-30 IMRT 6.0Gy x 12 fractions day 37 surgical removal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: clinically diagnosed malignant astrocytomas no evidence of CSF dissemination visible on MRI normal bone marrow, liver, and renal function written informed consent

Exclusion criteria

Exclusion criteria: large tumor (>6cm) sign of tent-herniation existence of extracranial malignant tumor pregnancy psychological disorder HIV positive patients history of pneumonitis history of radiation therapy for intracranial lesions

Design outcomes

Primary

Measure	Time frame
Occurrence of adverse events until 12 weeks after treatment	—

Secondary

Measure	Time frame
progression-free survival, overall survival	—

Countries

Japan

Contacts

Public ContactToshihiko Iuchi

Chiba Cancer Center Division of Neurological Surgery

tiuchi@chiba-cc.jp043-264-5431

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026